OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EDENE57

Eden Research PLC

Agricultural ChemicalsVerified

Eden Research PLC has a fully diluted share count of 803,362,994 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics for Eden Research PLC are not available in the current dataset, and no industry_config preferred metrics are provided for comparison. The company's revenue and earnings estimates are mixed, with a mean revenue estimate of 4.9 million GBP and a last actual revenue of 4.303 million GBP. Analysts have not provided a positive EPS estimate, with both the mean and last actual EPS at -0.00 GBP. Segment and geographic exposure data are not disclosed in the available source documents, making it impossible to assess revenue concentration or geographic diversification. The company's growth trajectory is uncertain, as no specific numeric deltas or revenue history are provided in the dataset. Analysts have set a mean price target of 20.00 GBP, with the median, high, and low price targets also at 20.00 GBP, indicating a consensus but no directional guidance. Risk factors include the inability to assess liquidity risk and the lack of disclosed dilution potential. No recent events, such as filings or transcripts, are available in the dataset to provide additional context on the company's risk profile.

30-day price · EDENE+0.30 (+10.0%)
Low$2.70High$3.80Close$3.30As of12 May, 00:00 UTC
Profile
CompanyEden Research PLC
TickerEDENE.L
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryAgricultural Chemicals
AI analysis

Business. Eden Research PLC is a company in the Agricultural Chemicals industry, specializing in the production and sale of chemical products for agricultural use.

Classification. Eden Research PLC is classified under the Basic Materials economic sector, Chemicals business sector, and Agricultural Chemicals industry with a confidence level of 0.92.

Eden Research PLC has a fully diluted share count of 803,362,994 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics for Eden Research PLC are not available in the current dataset, and no industry_config preferred metrics are provided for comparison. The company's revenue and earnings estimates are mixed, with a mean revenue estimate of 4.9 million GBP and a last actual revenue of 4.303 million GBP. Analysts have not provided a positive EPS estimate, with both the mean and last actual EPS at -0.00 GBP. Segment and geographic exposure data are not disclosed in the available source documents, making it impossible to assess revenue concentration or geographic diversification. The company's growth trajectory is uncertain, as no specific numeric deltas or revenue history are provided in the dataset. Analysts have set a mean price target of 20.00 GBP, with the median, high, and low price targets also at 20.00 GBP, indicating a consensus but no directional guidance. Risk factors include the inability to assess liquidity risk and the lack of disclosed dilution potential. No recent events, such as filings or transcripts, are available in the dataset to provide additional context on the company's risk profile.
Key takeaways
  • Eden Research PLC has no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities.
  • Analysts have set a consensus price target of 20.00 GBP, with no directional guidance provided.
  • The company's profitability metrics are not available, and no industry_config preferred metrics are provided for comparison.
  • Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
  • No recent events or filings are available to provide additional context on the company's risk profile.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyGBP
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.4M-$2.5M-$2.3M-$3.5M
FY-3$1.2M-$3.2M-$2.8M-$3.9M
FY-2$1.8M-$2.6M-$2.2M-$2.6M
FY-1$3.2M-$6.8M-$6.5M-$2.7M
FY0$4.3M-$2.2M-$1.9M-$3.9M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$16.9M$14.9M$7.3M
FY-3$15.0M$12.8M$3.8M
FY-2$12.9M$10.7M$2.0M
FY-1$16.6M$13.5M$7.4M
FY0$15.4M$11.8M$3.7M
PeriodOCFCapExFCFSBC
FY-4-$1.0M-$1.9M-$3.5M
FY-3-$1.6M-$1.7M-$3.9M
FY-2-$683.3k-$1.1M-$2.6M
FY-1-$1.7M-$1.8M-$2.7M
FY0-$1.0M-$2.6M-$3.9M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricEDENEActivity
Op margin5.5% medp25 -0.0% · p75 10.8%
Net margin4.1% medp25 0.1% · p75 8.8%
Gross margin20.5% medp25 12.4% · p75 29.7%
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-6.2% medp25 -13.4% · p75 -2.6%
Debt / equity37.1% medp25 10.3% · p75 82.0%
Observations
IR observations
Mean price target20.00 GBP
Median price target20.00 GBP
High price target20.00 GBP
Low price target20.00 GBP
Mean EPS estimate-0.00 GBP
Last actual EPS-0.00 GBP
Mean revenue estimate4,900,000 GBP
Last actual revenue4,303,000 GBP
Mean EBIT estimate-2,700,000 GBP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:09 UTC#bacda56d
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 20:06 UTCJob: 5331cc47